

Invitation to press and analyst briefing on the Year-End Report

Wednesday, February 14, 10:00 a.m. (CET) at Operaterrassen, Stockholm.

Bengt Ågerup, CEO and Erika Kjellberg Eriksson, CFO, will present the company and comment on the report.

Moderator: Lars Hevrenge, Enskilda Securites.

To participate, please register in one of the following ways: at www.financialhearings.com, or mail hearings@financialhearings.com or by phone + 46(0) 8 411 43 80.

Wednesday's presentation can also be followed live by telephone conference, which is accessible by dialling + 44 (0) 20 7806 1966 or Web Cast Live at.

www.financialhearings.com or www.q-med.com. The slide presentation will be available at www.q-med.com, on Wednesday, February 14 at the latest 10.00 a.m.

Q-Med's year-end report will be published around 08:00 a.m Wednesday, February 14.

Financial information from Q-Med during Year 2007:

3 May	Interim Report January – March 2007
3 May	Annual General Meeting
26 July	Interim Report January – June 2007
23 October	Interim Report January - September 2007

Queries should be addressed to: Camilla Schartau, Administrative Assistant

Tel: +46 (0) 733 87 14 22

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, produces, markets and sells implants for esthetic and medical use. All products are based on the company's patented technology for the production of stabilized non-animal hyaluronic acid, NASHA™. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, DUROLANE, for the treatment of osteoarthritis of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux (a malformation of the urinary bladder) in children and ZUIDEX, for the treatment of stress urinary incontinence in women. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has approximately 580 co-workers, with approximately 390 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is a Large Cap company on the OMX Nordic Exchange in Stockholm.

NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX, MACROLANE and all product names within the RESTYLANE family are trademarks that belong to Q-Med.

In the US, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.